Last reviewed · How we verify
Standard treatment of intravenous antibiotics
Standard treatment of intravenous antibiotics is a Small molecule drug developed by Henrik Nielsen. It is currently FDA-approved.
Henrik Nielsen's intravenous antibiotic is currently on the market, serving as a standard treatment option. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk lies in the lack of revenue data and key trial results, which may affect investor confidence and market positioning.
At a glance
| Generic name | Standard treatment of intravenous antibiotics |
|---|---|
| Sponsor | Henrik Nielsen |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis (NA)
- MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia (PHASE1)
- Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial (NA)
- IO Vancomycin Spine (PHASE2, PHASE3)
- Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) (PHASE2)
- Adjunctive Hyperbaric Oxygen Treatment for Patients With Necrotizing Soft-Tissue Infection (HOT-NSTI Trial). Investigator-initiated, International, Multicentre, Superiority, Randomized, Open-label, Clinical Trial. (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Minocycline in Stroke Study at Maimonides (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard treatment of intravenous antibiotics CI brief — competitive landscape report
- Standard treatment of intravenous antibiotics updates RSS · CI watch RSS
- Henrik Nielsen portfolio CI